Investigators described a syndrome of cholangiopathy in patients recovering from severe COVID-19 with abnormal liver tests and bile duct injury.
More patients receiving mRNA-1273 booster have serologic response with anti-receptor-binding domain antibody level of at least 100 U/mL.
Researchers assessed long-term outcomes of multidrug-resistant Enterobacterales colonization and infections among solid organ transplant recipients.
Favorable outcomes, minimal adverse effects seen in solid organ transplant recipients who received monoclonal antibody therapy for COVID-19.
Johns Hopkins investigators sought to evaluate antibody responses to a second SARS-CoV-2 mRNA vaccine dose among organ transplant recipients.
The NDA submission is supported by data from the multicenter, randomized, open-label, active-controlled phase 3 TAK-620-303 (SOLSTICE) trial.
A woman died of COVID-19 after receiving an infected double-lung transplant.
At 1 year after transplant, kidney allograft function, rejection rates similar regardless of donor hepatitis C status.
Increased utilization of HCV-positive liver allografts for LT is seen as one of the ways to counter national organ shortages, so researchers set out to better characterize the allografts that come from HCV-positive donors from specific regions.
Investigators evaluated the COVID-19 pandemic’s impact on patient access to liver transplantation.
